ProCE Banner Activity

FIRE-4: RAS/BRAF Mutation by Liquid Biopsy and Benefit From First-line FOLFIRI + Cetuximab in Patients With RAS-WT Metastatic Colorectal Cancer

Conference Coverage

The detection of RAS and BRAF mutations at baseline by liquid biopsy testing has prognostic and predictive utility, but the emergence of these mutations following treatment has no impact on survival in patients with mCRC who received 1L FOLFIRI + cetuximab in this analysis of the FIRE-4 trial.

Released: June 14, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.